Navigation Links
Onyx Pharmaceuticals Announces Third Quarter 2007 Financial Results Teleconference and Webcast
Date:10/25/2007

EMERYVILLE, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will webcast a teleconference with management to discuss third quarter 2007 financial results and provide a general business overview on Tuesday, November 6, 2007, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Financial results for the third quarter ended September 30, 2007 will be released earlier that day.

Interested parties may access a live webcast of the presentation at: http://events.streamlogics.net/conferenceplus/onyx/event003/index.asp or by dialing 847-413-3235 and using the passcode 19394894. A replay of the presentation will be available on the Onyx website or by dialing 630-652-3044 and using the passcode 19394894 approximately one hour after the teleconference concludes. The replay will be available through December 6, 2007.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. The company is developing Nexavar(R), a small molecule drug, with Bayer Pharmaceuticals Corporation. Nexavar is approved for the treatment of advanced kidney cancer in more than 50 countries. For more information about Onyx's pipeline and activities, visit the company's web site at: http://www.onyx-pharm.com.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer Pharmaceuticals Corporation.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... , ... February is American Heart Month sponsored by The American Heart Association. ... cardiovascular health for themselves, their families and their communities. , Heart disease is ... deaths are caused by heart disease. Nearly half of all Americans have at least ...
(Date:2/28/2017)... ... February 28, 2017 , ... Roxanna Cross will ... at the 11th Annual RISE Nashville Summit. RISE Nashville is the healthcare industry’s ... engagement strategies. , The discussion will include best practices for accurate identification and ...
(Date:2/27/2017)... ... February 27, 2017 , ... Robert E. Burke, MD, PhD, had a successful ... upbringing and life experiences could have led him down a much different path. , ... of Parenting, Perseverance and Pediatrics,” Dr. Burke shares a personal account of the tribulations ...
(Date:2/27/2017)... ... 27, 2017 , ... Elisa Guajardo Carothers is not your typical author. She went from working ... nun. Now, she writes about God, when she isn’t swimming as a performing mermaid. , ... is BS! (Before Satan),” she offers a comedic look at the dysfunctions of God’s family, ...
(Date:2/27/2017)... ... February 27, 2017 , ... POUGHKEEPSIE, N. Y. – Peer-reviewed guidelines from ... scientific studies, the Center for Disease Control ( CDC ) and Infectious Diseases Society ... B. Liegner, M.D. has compiled into a single volume a compelling argument that the ...
Breaking Medicine News(10 mins):
(Date:2/28/2017)... 27, 2017 Pulmonary drug delivery market is ... USD 36.10 billion in 2016, at a CAGR of ... route as an alternate route of drug delivery, rising ... incidence of respiratory diseases such as COPD, asthma, and ... during the forecast period. However, emerging markets and growth ...
(Date:2/28/2017)... -- Medical robots market is projected to reach USD ... 2016, growing at a CAGR of 21.1% in the ... Read the full report: http://www.reportlinker.com/p04730562-summary/view-report.html ... advancements, increase in funding for medical robots research, issuance ... investments are the key factors driving the growth of ...
(Date:2/28/2017)... global  pulse oximeters market  is expected to reach USD 2.8 billion by 2025, ... market is anticipated to witness significant growth during the forecast period, which can ... pulmonary disease (COPD), sleep apnea, cardiac arrhythmia, and ischemic conditions. ... ... View Research Logo ...
Breaking Medicine Technology: